Please assess the completion status of the following clinical trial:

Trial Title: Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent.~2. At-risk alleles associated with serum AAT \< 11 μM including null alleles and deficiency alleles. This must be documented in the subject's history or laboratory tests performed at screening.~3. At least 18 years of age.~4. Evidence of lung disease related to AAT deficiency, identified by at least one of the following:~   * FEV1\<80% predicted (post BD); or~  * Loss of lung function over a one year period of greater than 35ml in FEV1; or~  * HRCT evidence of pulmonary emphysema~5. For actively treated subjects, agreement to not receive any exogenous API product (i.e. washout) for five weeks prior to first study infusion.~6. Use of an effective means of contraception during the 24 weeks of study drug administration (this is applicable to both sexes).~7. Subjects on the BAL, bronchial brushing/biopsy group must be on inhaled corticosteroids at a stable dose two weeks prior the first Bronchoscopy and throughout the dosing period up the final bronchoscopy.~Exclusion Criteria:~1. Laboratory evidence of severe IgA deficiency (from medical history or by IgA testing at screening of at least 20% of lower range).~2. Current smoker or a history of smoking within the past 3 months.~3. History of allergy to plasma proteins.~4. Participation in another experimental drug or device trial within the past 30 days.~5. Evidence of uncontrolled hypertension (systolic ≥180 mm Hg, and/or diastolic ≥ 110 mm Hg on 3 consecutive occasions in the supine position)~6. Pulse ≥ 120/min (prior to the 1st infusion).~7. Abnormal screening or baseline laboratory measurements that in the opinion of the Investigator would affect subject safety.~8. Pregnancy or lactation.~9. Current life-threatening malignancy.~10. Previous organ transplant recipient.~11. History of infection with HCV, HBV and/or HIV 1 or 2, or (at baseline) infection indicated by laboratory measurements obtained at screening.~12. Acute respiratory tract infection or COPD exacerbation which required antibiotic and/or systemic steroid treatment within the past 6 weeks. Patient can be re-evaluated for enrollment 6 weeks after an exacerbation.~13. Any other condition which in the judgment of the investigator may interfere with the conduct of the study.~14. If an adequate home health care agency cannot be established by Centric Health Resources due to a potential subject's geographical location.~Exclusion criteria for subjects entering into the BAL and bronchial biopsy/brushing:~1. FEV1 \< 45% predicted (post-BD).~2. Inability to undergo bronchoscopy.~3. Allergy to lidocaine.~4. Exacerbation of COPD in the previous 6 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete